The American Physiological Society Press Release

press release logo

APS Contact: APS Communications Office

Email: communications@the-aps.org

Phone: 301.634.7209

Twitter: @APSPhysiology


Study May Explain Why Stroke Risk in Women Changes after Menopause

Findings in mouse cells may lead to treatments for brain injuries in men and women

Bethesda, Md. (January 19, 2016)—Risk of stroke in women may come down to a compound the body produces from estrogen known as 2-methoxyestradiol (2-ME). Furthermore, the compound’s therapeutic potential may extend beyond treating stroke in women to healing brain injuries in men, a new study in American Journal of Physiology—Endocrinology and Metabolism reports.

Microglia, the immune cells of the brain, maintain the brain and protect it from infection by consuming damaged cells and bacteria—a process called phagocytosis—and releasing toxic molecules to induce injured cells and bacteria to die. The same processes help “clean up the mess” after brain injury, such as after stroke or a head impact, says Edwin Jackson, PhD, of the University of Pittsburgh and the study’s collaborating investigator. However, overactive microglia may kill brain cells that otherwise would have survived the injury, worsening instead of healing the damage, Jackson explains.

Mouse microglial cells exposed to 2-ME multiplied less and had reduced immune activity: 2-ME stopped phagocytosis and the release of toxic molecules by microglia. “2-ME prevented microglia from becoming overly active,” Jackson says.

The findings help explain why risk of stroke in women changes after menopause. Menopause occurs when the ovaries stop producing the female sex hormones estrogen and progesterone. Prior to menopause, women have a lower risk of stroke compared to men. After menopause, women are at a higher risk. “Our study shows that microglia can metabolize (change) estradiol into 2-ME. So the female advantage before menopause may be in part the result of microglia making 2-ME from estradiol. Once estradiol levels collapse with menopause, the female advantage is lost. Administration of 2-ME could restore the female advantage,” Jackson says. Estradiol is an estrogen and the primary female sex hormone.

The use of 2-ME is not limited to women. “Although 2-ME is derived from estradiol, 2-ME is not estrogenic and can be used in both women and men,” Jackson notes. Because 2-ME “calms” microglia, it may be useful in treating or preventing other brain injuries including traumatic brain injury and chronic traumatic encephalopathy—the injury commonly found in professional football players and athletes in other contact sports, he says.

According to Jackson, current research on 2-ME supports that the compound is safe. “Unlike estradiol, 2-ME has anti-cancer activity, is cardio-protective and has beneficial activity in models of pulmonary artery hypertension. In fact, a slow-release formulation of 2-ME was developed and validated in a phase I clinical trial for pulmonary artery hypertension.”

The next step is to corroborate 2-ME’s effects, says Raghvendra Dubey of the University of Zurich and the study’s lead investigator. These findings in cells “provide important leads which need to be further confirmed using in vivo (animal) models of brain injury,” he says.

The article “2-Methoxyestradiol, an endogenous 17β-estradiol metabolite, inhibits microglial proliferation and activation via an estrogen receptor-independent mechanism” is published ahead-of-print in the American Journal of Physiology—Endocrinology and Metabolism.

NOTE TO JOURNALISTS: To schedule an interview with a member of the research team, please contact the APS Communications Office or 301-634-7209. Find more research highlights in the APS Press Room.

Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.

 


RelatedItems

Genes May Determine the Side Effects of Menopausal Hormone Therapy, Study Suggests

Released November 10, 2015 - Cardiovascular disease risk in women increases after menopause and is associated with the drop in estrogen levels. Menopausal hormone therapy could slow the progression, but oral formulations also increase the risk of blood clots. A new study reports that whether a woman will obtain cardiovascular benefits from certain types of hormone therapy may depend on her genes.

Not the Weaker Sex: Estrogen Protects Women Against the Flu, Study Finds

Released January 12, 2016 - A new study published in American Journal of Physiology—Lung Cellular and Molecular Physiology finds that the female sex hormone estrogen has anti-viral effects against the influenza A virus, commonly known as the flu. The study supports why the flu may hit men harder than women.

Sports-Related Concussion Negatively Affects Heart Rate, Blood Pressure

Released February 9, 2017 - A new study finds that concussion causes short-term impairment of the cardiovascular system but that these cardiovascular symptoms typically resolve within three days of the injury. The article is published ahead of print in the American Journal of Physiology—Regulatory, Integrative and Comparative Physiology.

From: 
Email:  
To: 
Email:  
Subject: 
Message:

~/Custom.Templates/PressRelease.aspx